Cure8 trial brief
Vitamin D deficiency is common in people with UC and vitamin D has plausible immune-modulating effects; this randomized trial tests whether supplementation improves inflammatory biomarkers and disease activity, which could inform adjunctive treatment approaches.
Adults with ulcerative colitis, gastroenterologists and IBD clinicians, researchers studying vitamin D or inflammatory biomarkers in IBD
The study randomized 60 adults with moderate UC in Lahore, Pakistan, to 12 weeks of standard treatment plus either vitamin D3 or placebo. Primary outcomes are changes in blood and fecal inflammatory markers and partial Mayo score; secondary outcomes include vitamin D status, dietary intake, and quality of life.
The intervention dose was cholecalciferol 50,000 IU fortnightly for 12 weeks. Exclusion included recent vitamin D supplementation within three months.
This entry is a clinicaltrials.gov trial record with protocol details and planned outcomes. The extract does not include results; wait for posted results or a peer-reviewed publication before changing treatment.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.
